The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis
Open accessAbstract
BACKGROUND: The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that of HCVAD plus dasatinib in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial. METHODS: The authors analyzed 110 patients with newly diagnosed Ph+ ALL who were enrolled in 2 consecutive, prospective, phase 2 clinical trials of frontline HCVAD with either dasatinib (63 patients) or ponatinib (47 patients). Propensity score analysis with 1:1 matching with the nearest neighbor matching method and inverse probability of treatment weighting (IPTW) analysis based on the propensity scores were performed to assess response rates, event‐free survival (EFS), and overall survival (OS) between the cohorts. RESULTS: Propensity score matching identified 41 patients in each cohort. With propensity score matching, the 3‐year EFS rates for patients treated with HCVAD plus ponatinib and HCVAD plus dasatinib were 69% and 46%, respectively (P =.04), and the 3‐year OS rates were 83% and 56%, respectively (P =.03). IPTW analysis using prematching cohorts demonstrated that patients treated with HCVAD plus ponatinib had significantly higher rates of minimal residual disease negativity by flow cytometry on day 21, complete cytogenetic response at complete response, major molecular response at complete response and at 3 months, and complete molecular response at 3 months. IPTW confirmed that treatment with HCVAD plus ponatinib was associated with longer EFS (P =.003) and OS (P =.001) compared with treatment with HCVAD plus dasatinib. CONCLUSIONS: The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL. Cancer 2016;122:3650‐6. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Cited by
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Metadata
- Authors
- Sasaki, K., Jabbour, E. J., Ravandi, F., Short, N. J., Thomas, D. A., Garcia‐Manero, G., Daver, N. G., Kadia, T. M., Konopleva, M. Y., Jain, N., Issa, G. C., Jeanis, V., Moore, H. G., Garris, R. S., Pemmaraju, N., Cortes, J. E., O'Brien, S. M., & Kantarjian, H. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-08
- Volume
- 122
- Issue
- 23
- Pages
- 3650-3656
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2483008971
- Cited by
- 204
- References
- 1
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis. https://app.cochat.ai/papers/10.1002/cncr.30231
- The paper
- Sasaki, K., Jabbour, E. J., Ravandi, F., Short, N. J., Thomas, D. A., Garcia‐Manero, G., Daver, N. G., Kadia, T. M., Konopleva, M. Y., Jain, N., Issa, G. C., Jeanis, V., Moore, H. G., Garris, R. S., Pemmaraju, N., Cortes, J. E., O'Brien, S. M., & Kantarjian, H. M. (2016). Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. https://doi.org/10.1002/cncr.30231
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.